Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants Ugo Pastorino, MD, Roberto Boffi, MD, Alfonso Marchianò, MD,

Slides:

Advertisements

Similar presentations

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Advertisements

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Long-Term Surveillance of Ground-Glass Nodules: Evidence from the MILD Trial Silva Mario, MD, Sverzellati Nicola, MD, PhD, Manna Carmelinda, MD, Negrini.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Screening with Low-Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer Mario Silva, MD, Carlotta Galeone, PhD, Nicola Sverzellati,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer Martin Reck, MD, PhD, Normand Blais,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months Arturo Navarro-Martin, MD, Samantha Aso, MD, Jon Cacicedo,

Trends in Subpopulations at High Risk for Lung Cancer

Electronic Updates for JTO Readers

Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever- Smokers for Lung Cancer Screening Fangyi Gu, ScD, MD, Li C. Cheung,

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher,

Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants Ugo Pastorino, MD, Roberto Boffi, MD, Alfonso Marchianò, MD,

Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial Marianna Christodoulou,

Regional Emphysema Score Predicting Overall Survival, Quality of Life, and Pulmonary Function Recovery in Early-Stage Lung Cancer Patients Jie Dai, PhD,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC Massimo Moro, MSc, Elisa Caiola, PhD,

Genetic Variation in GSTP1, Lung Function, Risk of Lung Cancer, and Mortality Marianne S. Nørskov, MSc, PhD, Morten Dahl, MD, DMSc, Anne Tybjærg-Hansen,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Screening with Low-Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer Mario Silva, MD, Carlotta Galeone, PhD, Nicola Sverzellati,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

One-year results of thoracic endovascular aortic repair for blunt thoracic aortic injury (RESCUE trial) Ali Khoynezhad, MD, PhD, FACS, Carlos E. Donayre,

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung.

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

It’s All in the “Swerve of the Curve”

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae Eiji Iwama, MD, PhD, Isamu Okamoto, MD, PhD, Hidetake Yabuuchi, MD, PhD,

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial Prakash Manoharan, MB ChB, Ahmed Salem, PhD, Hitesh Mistry, PhD,

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Spontaneous Smoking Cessation Before Lung Cancer Diagnosis

Phase-II Trial of Rebeccamycin Analog, a Dual Topoisomerase-I and -II Inhibitor, in Relapsed “Sensitive” Small Cell Lung Cancer Anita Schwandt, MD, Tarek.

Volume 20, Issue 8, Pages (August 2019)

Robert Comis, MD, The Passing of a “Lung Man”

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database Sukhmani.

Presentation transcript:

Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants Ugo Pastorino, MD, Roberto Boffi, MD, Alfonso Marchianò, MD, Stefano Sestini, MD, Elena Munarini, PhD, Giuseppina Calareso, MD, Mattia Boeri, PhD, Giuseppe Pelosi, MD, Gabriella Sozzi, PhD, Mario Silva, MD, Nicola Sverzellati, MD, Carlotta Galeone, PhD, Carlo La Vecchia, MD, Arianna Ghirardi, PhD, Giovanni Corrao, PhD Journal of Thoracic Oncology Volume 11, Issue 5, Pages 693-699 (May 2016) DOI: 10.1016/j.jtho.2016.02.011 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Flow diagram of inclusion criteria in the current study from previous pilot and Multicentric Italian Lung Detection (MILD) trials. Thirty subjects from the pilot study were randomized in the MILD trial after 5 years of screening. LDCT, low-dose computed tomography. Journal of Thoracic Oncology 2016 11, 693-699DOI: (10.1016/j.jtho.2016.02.011) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Kaplan-Meier overall mortality experienced by current and former smokers. Patients who still smoked and those who had stopped smoking during the last screening visit were regarded as current and former smokers, respectively. Journal of Thoracic Oncology 2016 11, 693-699DOI: (10.1016/j.jtho.2016.02.011) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Effect of smoking cessation on overall mortality. Hazard ratios (Cox model) and corresponding 95% confidence intervals estimating the effect of smoking cessation on mortality. Estimates are adjusted for covariates measured at baseline (sex, age, predicted forced expiratory volume in the first second of expiration, and average number of pack-years) and during follow-up (lung cancer detection and smoking status). HR, hazard ratio; CI, confidence interval. Journal of Thoracic Oncology 2016 11, 693-699DOI: (10.1016/j.jtho.2016.02.011) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions